MI:RNA says that current testing practices for Johne’s disease mean that identification of the disease is difficult, with current sensitivities of around 10-40% and little to no ability to diagnose early stages of infection.
The loss of productivity due to Johne’s to the UK agricultural economy is estimated to be in excess of £10 million annually.
MI:RNA says it is the first diagnostic testing company to use microRNA assay technology.
MicroRNAs are newly discovered biomarkers that manage the immune system and immune responses and act as regulators for disease progression or resolution.
This, says the company, makes them excellent biomarkers of disease, and when combined AI, can significantly improve identification of Johne’s and other complex conditions, and predict disease outcomes.
MI:RNA says this development will allow veterinary surgeons, farmers and pet owners to test for a variety of conditions, not just Johne’s.
Target areas include heart and kidney disease, osteoarthritis and bovine tuberculosis, along with effective general wellness and preoperative screening.
Eve Hanks, founder and CEO of MI:RNA, said: “Increasing market and global pressures on bovine protein production means that animal health has never been more important.
"This is a key area of research and development for MI:RNA and biomarker science combined with our unique AI-powered modelling, means that we can significantly improve animal health and reduce greenhouse gas output.
“The breakthrough that we’ve already achieved in Johne’s testing is unparalleled, and has provided an opportunity for MI:RNA to pitch our business concept in the USA to the The Kansas City Animal Health Summit.
"Following our presentation, we have now progressed through to the final selection stage for European Innovation Council funding for our work on Johne’s disease.
“In terms of future applications, microRNAs can assist with vital drug discovery, progressing future diagnostic testing and understanding disease pathways more effectively.
"We’ve already made remarkable progress and we know that with the continued backing of our tech, AI and health experts and with the correct funding, that we can do so much more.”
PS: Whilst you're here, take a moment to see our latest job opportunities for vets.